Table of Contents OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2020 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or other jurisd ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2021 was $38.5 million, representing a 17% year-over-year increase [11][26] - Average number of provider clients increased to 1,737, up 10% year-over-year [11] - Average revenue per provider client rose to $17,490, a 5% year-over-year increase [11] - Adjusted EBITDA was $1.2 million, down approximately $1.8 million year-over-year due to continued investments in long-term growth [11][34] - Cash on the balance sheet was $254.1 million, up $169.9 million from July 31 [35] Business Line Data and Key Metrics Changes - Subscription and related services revenue was $17.5 million, up 20% year-over-year [26] - Payment processing fee revenue reached $12.9 million, a 12% year-over-year increase [27] - Life Sciences revenue was $8.1 million, up 21% year-over-year, reflecting strong execution and demand [11][29] Market Data and Key Metrics Changes - Patient visit trends recovered to pre-pandemic levels during September and were sustained through the end of the quarter [27] - The company noted that the sales team focused on getting solutions to providers and patients who needed them during the pandemic [43] Company Strategy and Development Direction - The company is focused on long-term growth and has prioritized investments in R&D, expecting to accelerate spending in the coming quarters [31][37] - A leadership transition is planned with the current CFO retiring and a new CFO set to take over in May 2021 [14][15] - The company is committed to enhancing its environmental, social, and governance (ESG) initiatives, particularly in gender equality [21][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth drivers and the ability to meet growth objectives despite uncertainties related to COVID-19 [42] - The company expects revenue for the full fiscal year 2021 to be between $146 million and $147 million, with growth projected at 20% to 25% for fiscal year 2022 [37] Other Important Information - The company has transitioned to a fully remote operation and allowed its New York City office lease to expire [18][19] - The company is actively recruiting and expanding its sales and implementation teams to capture market opportunities [63] Q&A Session Summary Question: How will the quantified market opportunity contribute to growth? - Management indicated that it is a multiyear driver of growth, providing comfort in guidance moving forward [42] Question: What is the reason for the lower revenue per provider client despite strong client growth? - Management attributed this to a focus on getting solutions to providers and patients during the pandemic [43] Question: Can you highlight areas of increased R&D spending? - Management stated that they will continuously communicate where they are investing and will only do so after having clients using those products [47] Question: What are the underlying assumptions for the 20% to 25% guidance for fiscal year 2022? - Management emphasized that the guidance is based on current knowledge and not a prediction of future COVID impacts [54] Question: Can you provide details on the retirement of the CFO? - The current CFO will remain as an advisor after retirement, ensuring a smooth transition [56] Question: What is the current state of the sales force? - The sales organization has approximately 40 salespeople and around 100 SDRs, with a focus on ramping back up post-pandemic [131] Question: Are there any pricing pressures from competing solutions? - Management noted that while competition exists, they have not seen significant downward pressure on pricing [138]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or other jurisdict ...

Phreesia, Inc. (NYSE:PHR) Q2 2021 Earnings Conference Call September 9, 2020 8:30 AM ET Company Participants Balaji Gandhi - VP, IR Chaim Indig - CEO Thomas Altier - CFO Conference Call Participants Anne Samuel - JPMorgan Ryan Daniels - William Blair Stephanie Davis - SVB Leerink John Ransom - Raymond James Donald Hooker - KeyBanc Sean Wieland - Piper Sandler Glen Santangelo - Guggenheim Securities Daniel Grosslight - Citi Sean Dodge - RBC Capital Markets David Larsen - Verity Research Operator Good morning ...

Investor Presentation September 2020 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," "could," "appears," "shal ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or other jurisdic ...

Phreesia, Inc. (NYSE:PHR) Q1 2021 Earnings Conference Call June 9, 2020 8:30 AM ET Company Participants Balaji Gandhi - VP, IR Chaim Indig - CEO Thomas Altier - CFO Conference Call Participants Anne Samuel - J.P. Morgan Unidentified Analyst - William Blair & Company Stephanie Davis Demko - SVB Leerink LLC Sean Wieland - Piper Sandler Companies Matthew Gillmor - Robert W. Baird & Co. John Ransom - Raymond James Donald Hooker - KeyBanc Capital Markets Inc. Glen Santangelo - Guggenheim Securities Jamie Stockto ...

Investor Presentation April 2020 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," "could," "appears," "shall," ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification No.) 432 Park Avenue South, 12 th Floor New York, NY (Address of Principal Executive Offices) (Zip Code) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2020 OR ☐ TRANSITION REPOR ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (I.R.S. Employer Identification No.) (888) 654-7473 (Registrant's telephone number, including are ...